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In chronic pain states, the neurotrophin brain-
derived neurotrophic factor (BDNF) transforms the
output of lamina I spinal neurons by decreasing syn-
aptic inhibition. Pain hypersensitivity also depends
on N-methyl-D-aspartate receptors (NMDARs) and
Src-family kinases, but the locus of NMDAR dysre-
gulation remains unknown. Here, we show that
NMDAR-mediated currents at lamina I synapses are
potentiated in a peripheral nerve injury model of
neuropathic pain. We find that BDNF mediates
NMDAR potentiation through activation of TrkB and
phosphorylation of the GluN2B subunit by the Src-
family kinase Fyn. Surprisingly, we find that Cl-
dependent disinhibition is necessary and sufficient
to prime potentiation of synaptic NMDARs by
BDNF. Thus, we propose that spinal pain amplifica-
tion is mediated by a feedforward mechanism
whereby loss of inhibition gates the increase in syn-
aptic excitation within individual lamina I neurons.
Given that neither disinhibition alone nor BDNF-
TrkB signaling is sufficient to potentiate NMDARs,
we have discovered a form of molecular coincidence
detection in lamina I neurons.INTRODUCTION
Pain hypersensitivity depends on maladaptive changes in
neuronal activity within the peripheral, spinal, and brain nocicep-
tive networks. The spinal nociceptive network in the dorsal horn
is an interconnected matrix of inputs from primary afferents as
well as from inhibitory and excitatory local circuit neurons and
descending efferent fibers. Neurons in dorsal horn lamina I are
an essential component of the spinal nociceptive network and
are critical for acute as well as chronic pain signaling (Braz
et al., 2014; Prescott et al., 2014).Cell Repo
This is an open access article under the CC BY-NThe output of lamina I neurons is controlled by a delicate
balance between synaptic excitation and inhibition and shifting
the balance toward excitation leads to chronic pain (Woolf and
Salter, 2000). This balance may be disrupted by reducing synap-
tic inhibition (disinhibition). A growing body of evidence has
demonstrated that brain-derived neurotrophic factor (BDNF) is
a major driver of disinhibition at lamina I synapses (Beggs and
Salter, 2013; Ferrini and De Koninck, 2013). In the context of pe-
ripheral nerve injury (PNI), BDNF is released from activated mi-
croglia and binds to TrkB receptors on lamina I neurons (Beggs
et al., 2012; Coull et al., 2005). Activated TrkB receptors down-
regulate the potassium-chloride co-transporter, KCC2, resulting
in increased intracellular Cl, attenuated GABAergic inhibition,
and increased action potential firing in lamina I neurons (Coull
et al., 2003, 2005; Keller et al., 2007).
Pain-producing changes in the balance between excitation
and inhibition may also be mediated by enhancing excitation
within the spinal nociceptive network. Excitation is driven by glu-
tamatergic synaptic transmission, and the N-methyl-D-aspar-
tate receptor (NMDAR) class of glutamate receptors is promi-
nently implicated in spinal mechanisms of chronic pain
(Bourinet et al., 2014). Blocking NMDAR activity of receptors
containing the GluN2B subunit using pharmacological or genetic
approaches blocks pain hypersensitivity in animal models of
chronic pain. Moreover, behavioral and biochemical studies
show that enhancement of NMDAR function by Src family ki-
nases is critical for pain hypersensitivity (Abe et al., 2005; Liu
et al., 2008).
A major open question is where is the critical locus of change
in glutamate receptor function within the highly interconnected
matrix that is the spinal nociceptive network. Here, we tested
the hypothesis that in pain hypersensitivity, there is enhanced
glutamatergic synaptic transmission onto neurons in lamina I.
In order to properly characterize the postsynaptic responses at
lamina I glutamatergic synapses, it was necessary to avoid acti-
vating the nociceptive network, which includes prolonged poly-
synaptic excitatory responses that contaminate direct excitatory
synaptic responses (Todd, 2010). Thus, we studied miniature
excitatory postsynaptic currents (mEPSCs) in lamina I neurons,
as these mEPSCs are direct synaptic responses (Hildebrandrts 17, 2753–2765, December 6, 2016 ª 2016 The Author(s). 2753
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. NMDAR mEPSCs in Lamina I Neu-
rons Are Reversibly Potentiated by BDNF in
the PNI Model of Neuropathic Pain
(A) Average outward mEPSC traces at +60 mV from
lamina I neurons in spinal slices of naive rats in the
absence (black, n = 20) and presence (gray, n = 3) of
100 mM APV.
(B) Left: averagemEPSC tracesat+ 60mV in ratswith
PNI (gray, n=9)compared tonaive rats (black, n=20).
Right: average mEPSC traces at60 mV in rats with
PNI (gray, n=5)compared tonaive rats (black, n=13).
(C) Left: averaged mEPSC traces from rats with PNI
during an initial recording period (gray) and during a
final period (30–50 min) of recording (black, n = 7).
Right: time course of NMDAR charge transfer
(averaged every 10 min, n = 4 each).
(D) Average mEPSC traces from naive rats (black)
and rats with PNI (gray) as well as from rats with PNI
that had slices treated with 200 ng/mL TrkB-Fc
before recording (light gray, n = 9). Current traces
are represented as means (dark lines) ± SEM (ligh-
ter bars) of mEPSCs from all averaged cells. Scale
bars, 100 ms (x axes); 5 pA (y axes).et al., 2014). We found that NMDAR-mediated mEPSCs were
enhanced in a PNI model of chronic pain. Because the enhance-
ment was mediated by BDNF-TrkB signaling, we tested whether
there is functional crosstalk between potentiation of NMDAR-
mediated excitation and loss of GABAergic inhibition. We
found that BDNF-mediated disinhibition led to enhancement of
GluN2B NMDAR responses via Fyn activation in naive animals
and, conversely, blocking disinhibition reversed the enhance-
ment after PNI. Thus, our findings show that enhanced excitation
of lamina I neurons is gated by disinhibition.
RESULTS
The NMDAR but Not the AMPAR Component of mEPSCs
in Lamina I Neurons Is Increased following Peripheral
Nerve Injury
To investigate synaptic glutamatergic responses in lamina I neu-
rons, we made whole-cell patch clamp recordings on visualized
neurons in lamina I in acute spinal slices from adult rats. When
we recorded at a holding potential of 60 mV, we observed
spontaneously occurring, rapidly rising, and decaying inward
currents that were eliminated by the AMPAR antagonist CNQX,
demonstrating that these were mEPSCs. Holding the membrane
potential at +60 mV revealed a slowly decaying NMDAR compo-
nent of themEPSCs thatwas blockedby 100 mMAPV (Figure 1A).
Thus, the currents we recorded here corresponded to bi-compo-
nent, AMPAR/NMDAR mEPSCs described previously (Hilde-
brand et al., 2014). To clearly separate the NMDAR-mediated
component from the AMPAR-mediated component during re-
cordings at +60 mV, we calculated the NMDAR component as
that beginning 40 ms after the onset of the mEPSC and extend-
ing to 500 ms after mEPSC onset (Table S1). AMPAR currents
were studied at a holding potential of 60 mV.
To determine whether these glutamatergic synaptic re-
sponses of lamina I neurons are affected during pathological
pain processing, we studied mEPSCs in neurons from rats
that had received a PNI (Mosconi and Kruger, 1996; Pitcher2754 Cell Reports 17, 2753–2765, December 6, 2016et al., 1999). PNI is widely used as a model of peripheral neuro-
pathic pain and pain hypersensitivity is inferred by a lowering of
the mechanical paw withdrawal threshold ipsilateral to the nerve
injury. We included only animals in which the paw withdrawal
threshold was significantly reduced compared to the same
paw before PNI (n = 23 animals). The recordings were made
from slices taken from animals 10–17 days after PNI, when the
mechanical hypersensitivity has reached maximum. We found
that the frequency of mEPSCs was not affected by PNI (PNI:
4.5 ± 1.8 Hz, n = 5; naive 3.6 ± 0.9, n = 13, p = 0.61). Moreover,
we found that the AMPAR mEPSCs in lamina I neurons were not
altered in neurons from animals with PNI (Figure 1B): peak
(23.6 ± 1.2 pA), rise time (0.9 ± 0.2 ms), and decay time con-
stant (5.9 ± 0.9 ms) of the AMPAR mEPSCs after PNI (n = 5 neu-
rons) were not significantly different than those from naive rats
(22.0 ± 1.2 pA, p = 0.45; 1.2 ± 0.1 ms, p = 0.27; 6.7 ±
0.5 ms, p = 0.43, respectively; n = 13 neurons). By contrast,
we found that the NMDAR component of the mEPSCs was
significantly increased after PNI (Figure 1B). We used charge
transfer as a robust measure of the NMDAR component of the
mEPSCs (Hildebrand et al., 2014) and observed that the charge
transfer in neurons from rats with PNI (5.27 ± 0.35 pC, n = 9 neu-
rons) was greater than that in naive rats (3.20 ± 0.22 pC, n = 20
neurons; p = 0.000021). The NMDAR component of themEPSCs
in sham-operated rats (2.75 ± 0.52 pC, n = 6) was not different
from that in naive rats (p = 0.37). From these findings, we
conclude that the NMDAR component, but not the AMPAR
component, of mEPSCs in lamina I neurons was significantly
potentiated following PNI.
BDNF-TrkB Signaling Mediates the Potentiation of
NMDAR mEPSCs by PNI
Strikingly, we observed a progressive decrease in the NMDAR
component of mEPSCs during recordings of lamina I neurons
from rats with PNI but not during recordings in neurons from
naive rats (Figure 1C; Table S2). By comparison, the AMPAR
component of the mEPSCs was stable during recording from
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Figure 2. BDNF Is Sufficient to Facilitate
NMDAR mEPSCs
(A) Average initial mEPSC traces in slices of naive
rats treated with (gray, n = 14) or without (black,
n = 20) 50 ng/mL BDNF.
(B) Average mEPSC traces from BDNF-treated
slices during initial (gray) and final (black, 20 to
50 min) periods of recording (n = 10).
(C)mEPSC traces froma rat with PNI during an initial
recording period (gray), a later recording period
(black), and subsequent perfusion of 100 ng/mL re-
combinant BDNF protein for 5–15 min (dark gray).
(D) Average initial mEPSC traces (top) and associ-
ated NMDAR charge transfer values (bottom) from
spinal slices of naive rats pre-treated with BDNF
alone (black, n = 14), BDNF and 2 mg/mL anti-TrkB
(gray, n = 7), or BDNF followed by intracellular
100 nM K252a during recording (light gray, n = 8).
*p < 0.05 compared to BDNF pre-treatment alone.
(E) Plot of final charge transfer values normalized to
initial values. *p < 0.05 compared to initial charge
transfer values for given treatment. Inset, average
mEPSC traces at +60 mV during initial (gray) and
final (black) recording periods for slices pre-treated
with BDNF and anti-TrkB (n = 5). Scale bars, 100 ms
(x axes); 5 pA (y axes).
All current traces and plots are represented as
means ± SEM.either PNI or naive rats (not illustrated). In neurons from rats with
PNI, the NMDAR charge transfer decreased from an initial value
of 5.17 ± 0.47 pC to 3.08 ± 0.37 pC (n = 7 neurons, p = 0.000030)
after 30 min of recording. The NMDAR charge transfer at the end
of the recordings from these neurons was not different from the
charge transfer in neurons from naive rats (p = 0.47; Figure 1C).
These findings indicate that the potentiation of the NMDAR
component of the mEPSCs in neurons from rats with PNI was
gradually lost during the recordings and that the NMDAR
mEPSCs returned to the basal level observed in neurons from
naive animals.
The neurons were continuously superfused with extracellular
recording solution during the recording period, and we ques-
tioned whether the decrease in NMDAR mEPSCs in neurons
from rats with PNI was due to progressive loss of an endoge-
nous, extracellular potentiating substance. Given the key role
of BDNF in pain hypersensitivity (Beggs and Salter, 2013; Ferrini
and De Koninck, 2013), we considered the possibility that
BDNF might be such a potentiating substance. To test this pos-
sibility, we treated spinal cord slices from rats with PNI with a
BDNF-sequestering fusion protein, TrkB-Fc (Ninkina et al.,
1997), beginning at least 10min prior to recording and continuing
throughout the recording period. In contrast to the recordings
without TrkB-Fc treatment, we found that the NMDAR charge
transfer was stable during recordings (n = 6, p = 0.30) in neurons
from PNI rats treated with TrkB-Fc (200 ng/mL). Moreover, the
initial NMDAR charge transfer in neurons from PNI rats treated
with TrkB-Fc was significantly less than that in PNI neurons not
treated with TrkB-Fc (n = 9, p = 0.014, Figure 1D). In addition,
the NMDAR charge transfer in PNI neurons treated with TrkB-
Fc was not different from the final NMDAR charge transfer in
neurons from PNI rats (n = 9 and 7 neurons, respectively,p = 0.62) nor from that in neurons from naive rats (n = 20 neurons,
p = 0.62). Together, these findings indicate that prior to the
beginning of the recordings in neurons from PNI animals, the
pre-treatment with TrkB-Fc occluded the decline in NMDAR
mEPSCs. The observation that the NMDAR charge transfer in
neurons from PNI rats remained constant or increased during
the first 10 min of recording suggests that the decline in NMDAR
responses was not due to loss of an intracellular signal through
dialysis of the patch pipette solution. Therefore, we conclude
that the potentiation of NMDAR mEPSCs in lamina I neurons
following PNI depends upon endogenously released BDNF.
To test whether BDNF is sufficient to cause potentiation of
NMDAR mEPSCs, we pre-treated spinal slices from naive ani-
mals with recombinant BDNF (50 ng/mL BDNF, 75 ± 3 min,
n = 14 neurons). We found that the initial NMDAR charge transfer
in BDNF-pre-treated slices (5.03 ± 0.37 pC; n = 14 neurons) was
significantly larger than that in neurons from untreated slices
(3.20± 0.22pC; n =20neurons; p= 0.000088; Figures 2A). During
these experiments, we stopped the BDNF treatment just prior to
recording and observed a progressive decrease in the NMDAR
mEPSCs (Figure 2B) comparable to the decline in the NMDAR
component during recordings in neurons from PNI rats (cf. Fig-
ure 1C). To determine whether we could reverse the loss of
NMDAR mEPSC charge transfer during recordings from PNI an-
imals, we applied BDNF after the currents had declined (Fig-
ure 2C; Table S3). NMDAR currents significantly increased by
55% ± 14% (n = 5 neurons, p = 0.0086) following BDNF adminis-
tration (100 ng/mL, 7–20 min), indicating that the decline in
NMDARmEPSCswas rescued by exogenous BDNF. The finding
that NMDAR responseswere potentiated by exogenousBDNF at
this later time point further supports the conclusion that the initial
decline in NMDARs was not due to whole-cell dialysis. Together,Cell Reports 17, 2753–2765, December 6, 2016 2755
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Figure 3. The Potentiation of NMDAR
mEPSCs by BDNF/ PNI Requires Fyn but
Not Src
(A) Time course of NMDAR charge transfer with
either 1 mM EPQ(pY)EEIPIA (gray, n = 4) or 1 mM
EPQYEEIPIA (black, n = 3) in the intracellular pipette
solution. Inset, average mEPSC traces during initial
(black) and final (gray, 40+ min) recording periods,
with1mMEPQ(pY)EEIPIA in the intracellular solution.
(B) Left: plot of initial NMDAR charge transfer for
slices pre-treatedwithBDNF (shaded, cf. Figure 3A),
BDNFand1mMPP2 (gray, n=6), orBDNFand10mM
SU6656 (light gray, n = 5). *p < 0.05 compared to
BDNF pre-treatment alone. Right: plot of normalized
charge transfer values for the same pre-treatment
conditions as left, with inset average mEPSC traces
for pre-treatment with BDNF and PP2 (top) or BDNF
and SU6656 (bottom). *p < 0.05 compared to initial
charge transfer value for given treatment.
(C) Left: plot of initial NMDAR charge transfer for
slices pre-treatedwithBDNFand10mMTAT-Fyn39-
57 (gray, n = 9), BDNF and 10 mM TAT-Scbld-Fyn
(black, n = 7), or BDNF and 10 mM TAT-Src40-58
(light gray, n = 9). *p < 0.05 compared to BDNF
pre-treatment alone. Right: average mEPSC traces
during initial (gray) andfinal (black) recording periods
for the pre-treatment conditions to the left.
(D) Left: plot of initial NMDAR charge transfer from PNI rats during control recordings (black, n = 9) or recordings with intracellular dialysis of Fyn39-57 (gray,
n = 6) or Src40-58 (light gray, n = 7). Middle: average initial mEPSCs of PNI rats with intracellular Src40-58 (light gray) or intracellular Fyn39-57 (gray). Right: plot of
normalized charge transfer values during initial and final recording periods for the same treatment conditions in PNI rats as left, with inset average mEPSC traces.
Scale bars, 100 ms (x axes); 5 pA (y axes).
All current traces and plots are represented as means ± SEM.these findings indicate that BDNF is not only necessary for the
potentiation following PNI but is also sufficient to induce a poten-
tiation of synaptic NMDAR currents in lamina I neurons.
To determine whether the potentiation of NMDARmEPSCs by
BDNF is mediated through activation of its cognate receptor,
TrkB, we utilized a function-blocking anti-TrkB antibody (anti-
TrkB) (Coull et al., 2005; Prescott et al., 2014). In spinal slices
from naive rats, co-treatment of anti-TrkB (2 mg/mL) with BDNF
(n = 7 neurons) prevented the potentiation of NMDAR mEPSCs
(Figure 2D) and the subsequent decline in NMDARmEPSCs (Fig-
ure 2E) seen in neurons pre-treated with BDNF but not anti-TrkB
(cf. Figure 2A). To test whether TrkB was activated directly in the
neuron in which NMDARmEPSCs were potentiated, we intracel-
lularly administered the TrkB inhibitor, K252a (Tapley et al.,
1992), into the recorded neuron through the patch pipette.
Because we administered K252a directly into the cell, we used
near IC50 concentrations (100 nM) to minimize inhibition of
TrkB in neighboring neurons. In neurons with intracellularly
administered K252a (n = 8 neurons), we observed neither the
BDNF-induced increase in NMDAR charge transfer (Figure 2D)
nor the subsequent decline in NMDAR mEPSCs during record-
ings (Figure 2E). Therefore, we conclude that the potentiation
by BDNF of synaptic NMDAR responses in a given lamina I
neuron is mediated by activating TrkB on that neuron.
Potentiation of NMDAR mEPSCs by BDNF Requires Fyn
Kinase Activity
AsupregulationofNMDARsbySrc family protein tyrosine kinases
(Wang andSalter, 1994) is implicated inmodels of pain hypersen-2756 Cell Reports 17, 2753–2765, December 6, 2016sitivity (Bourinet et al., 2014), we investigated whether Src family
kinases (SFKs) participate in the BDNF-mediated potentiation of
NMDAR mEPSCs in lamina I neurons. First, we found that the
phosphopeptide SFK activator EPQ(pY)EEIPIA (1 mM, n = 4 neu-
rons, p = 0.0056), but not the inactive EPQYEEIPIA (1 mM, n = 3
neurons, p = 0.47), caused a progressive increase in NMDAR
charge transfer when administered intracellularly through the
patch pipette (Figure 3A). Thus, in lamina I neurons synaptic
NMDAR currents can be upregulated by activating SFKs.
Next, we tested for SFK involvement in BDNF-mediated
potentiation of NMDAR mEPSCs. We found that the BDNF-
induced increase in NMDAR charge transfer was prevented
(Figure 3B, left) by pre-administering the SFK inhibitor PP2
(1 mM; n = 6 neurons). Pre-treating with PP2 also precluded the
in-recording decline in NMDAR charge transfer normally
observed in neurons pre-treated with BDNF without PP2 (Fig-
ure 3B, right). Administering PP2 acutely to spinal slices from
naive animals had no effect on NMDAR charge transfer (n = 4
neurons, p = 0.46; Figure S1), implying that PP2 does not directly
inhibit NMDARs. Also, the lack of effect of PP2 on NMDAR
mEPSCs indicates that in lamina I neurons under basal condi-
tions there is no ongoing upregulation of NMDAR mEPSCs by
SFKs. The effects of PP2 on BDNF potentiation of NMDARs
were mimicked by a structurally distinct SFK inhibitor, SU6656
(10 mM; n = 5 neurons; Figure 3B). Thus, we conclude that SFK
activity is necessary for the BDNF-mediated potentiation of
NMDAR mEPSCs in lamina I neurons.
Because two individual SFK members, Src and Fyn, are impli-
cated in chronic pain hypersensitivity (Abe et al., 2005; Liu et al.,
2008), we tested whether Src or Fyn is required for the potentia-
tion of NMDAR mEPSCs by BDNF. We utilized membrane-
permeable TAT-fusion peptide inhibitors that differentially block
the upregulation of NMDAR currents by Src kinase itself, TAT-
Src40-58 (Liu et al., 2008), or by Fyn kinase, TAT-Fyn39-57
(Yang et al., 2012). We examined the effects of the TAT peptides
(10 mM) on the BDNF-induced potentiation in lamina I neurons
from naive rats. Pre-treating with TAT-Fyn39-57 together with
BDNF (n = 9 neurons) prevented the potentiation of NMDAR
mEPSCs (Figure 3C) and the subsequent decline in NMDAR
mEPSCs (Figure 3C) observed in neurons pre-treated with
BDNF alone. However, pre-treatment with a TAT-fusion peptide
in which the Fyn39-57 sequence was scrambled (TAT-Scbld-
Fyn, n = 7 neurons) did not prevent the BDNF potentiation: the
NMDAR charge transfer in neurons treated with TAT-Scbld-
Fyn was not different from that in neurons treated with BDNF
alone and the characteristic in-recording decline in the NMDAR
mEPSCs was observed (Figure 3C). In contrast to TAT-Fyn39-
57, TAT-Src40-58 (n = 9 neurons) did not prevent the BDNF-
induced increase in NMDAR charge transfer nor the subsequent
in-recording decline in the NMDAR mEPSCs (Figure 3C).
As these findings indicate that the potentiation of NMDAR
mEPSCs by BDNF depends upon Fyn kinase but not Src kinase,
we tested whether Fyn, but not Src, is required for the potentia-
tion of NMDAR mEPSCs following PNI. In these experiments,
we utilized membrane-impermeant versions of the peptides—
Fyn39-57 and Src40-58 (30 mg/mL)—which were administered
directly into the neurons during recordings to allow us to deter-
mine whether Fyn, or Src, was required in the neuron under
study. We found in recordings from PNI animals that the NMDAR
charge transfer in neurons in which Fyn39-57 was administered
intracellularly (n = 6 neurons) was significantly less than that
in neurons without Fyn39-57 (Figure 3D, left). In addition, there
was no in-recording decline in NMDAR mEPSCs in neurons
recorded with Fyn39-57 (Figure 3D, right). Moreover, after PNI
the NMDAR charge transfer in neurons recorded with Fyn39-
57 was not different from that in neurons from naive rats not
receiving Fyn39-57 (PNI + Fyn 3.31 ± 0.34 pC, n = 6 neurons;
naive 3.20 ± 0.22 pC, n = 20 neurons, p = 0.81). The effects of
Fyn39-57 on NMDAR charge transfer in neurons from PNI rats
were not produced by intracellularly administering Src40-58
(n = 7 neurons): NMDAR charge transfer and subsequent in-
recording decline were not different from those in neurons
without peptide administration (Figure 3D).
BDNF Activates Fyn but Not Src to Drive the
Phosphorylation and Potentiation of GluN2B NMDARs
Because Fyn was required for the potentiation of synaptic
NMDARs by either BDNF or nerve injury, we next tested whether
activation of Fyn was sufficient to potentiate NMDARs at adult
lamina I synapses. We found that activation of intracellular
SFKs with EPQ(pY)EEIPIA significantly (p < 0.05) increased
NMDAR mEPSCs when Src was blocked with intracellular
Src40-58 (n = 5) but not when Fyn was blocked with intracellular
Fyn39-57 (n = 6) (Figure 4A). We previously found that SFKs are
differentially coupled to specific NMDAR GluN2 subunits, with
Src potentiating GluN2A-containing receptors and Fyn potenti-
ating GluN2B-containing receptors (Yang et al., 2012). Here,we found that the component of NMDAR mEPSCs that was
potentiated by BDNF had a decay time constant of 276 ms,
which is consistent with NMDARs containing GluN1 together
with GluN2B (Figure 4B). We therefore tested whether GluN2A
and/or GluN2B is required for the potentiation of NMDAR
mEPSCs by BDNF. In slices treated with BDNF and a GluN2A
selective antagonist, TCN-201 (3 mM), the initial NMDAR charge
transfer (4.24 ± 0.22 pC; n = 8) was significantly greater than sli-
ces treated with the GluN2A antagonist alone (2.86 ± 0.25 pC;
n = 12; p = 0.0012), with the same decline in NMDAR mEPSCs
observed for BDNF pre-treatment alone (Figure 4C). In contrast,
treating slices with BDNF and a GluN2B selective antagonist,
Ro25-6981 (1 mM), prevented the potentiation and subsequent
decline of NMDAR mEPSCs (Figure 4C): the initial NMDAR
charge transfer was not significantly different for BDNF and
Ro25-6981 (1.54 ± 0.22 pC; n = 6) compared to treatment with
Ro25-6981 alone (1.23 ± 0.17 pC; n = 12; p = 0.30).
Next, we used biochemical approaches to investigate whether
BDNF treatment altered Fyn-meditated phosphorylation and
synaptic localization of NMDAR subunits in the superficial dorsal
horn (SDH). We first immunoprecipitated Fyn or Src from the
synaptosomal fraction of SDH tissue, followed by detection
with phospho-SFK antibodies. Phosphorylation of two tyrosine
residues regulate the activity of these kinases, with phosphoryla-
tion of Tyr420 activating Fyn (Tyr416 in Src) and phosphorylation
of Tyr531 inhibiting Fyn (Tyr527 in Src) (Ingley, 2008; Salter and
Kalia, 2004). Treatment of SDH tissue with BDNF led to a signif-
icant increase in Fyn phosphorylation at Tyr420 (p = 0.012) and a
concomitant decrease at Tyr531 (p = 0.014), indicating increased
activation of Fyn at SDH synapses (n = 6 slices, Figure 5A). In
contrast, we found no changes in Src phosphorylation at either
Tyr416 (p = 0.58) or Tyr527 (p = 0.48) (n = 6, Figure 5A) as well
as no change in total Src or Fyn protein levels (Figure 5B, data
not shown).
We also tested the phospho-SFK antibody without immuno-
precipitation and found a significant increase in SFK phosphory-
lation at this Tyr residue (Tyr420/Tyr416, Figure 5B, top; Data S1).
As phosphorylation of Src was not altered by BDNF (Figure 5A),
we conclude that this likely reflects an increase in Fyn phos-
phorylation at Tyr420. Activated Fyn potentiates GluN2B-contain-
ing NMDARs by phosphorylating Tyr1472 on the GluN2B subunit
(Salter and Kalia, 2004). Consistent with our findings of a
Fyn-dependent potentiation of GluN2B-mediated synaptic
responses, we found increased phosphorylation of GluN2B
at Tyr1472 upon BDNF treatment (p = 0.023) as well as increased
localization of GluN2B protein in SDH synaptosomes (p = 0.012)
(n = 8 slices, Figure 5B, middle). In contrast, we found that BDNF
treatment did not alter the phosphorylation of GluN2A at an anal-
ogous residue (Tyr1325) (p =0.84) nor totalGluN2A levels (p=0.59)
(n = 8 slices, Figure 5B, bottom). Moreover, BDNF treatment had
no effect on Fyn or GluN2B phosphorylation or expression in
synaptosomes from deep dorsal horn and ventral horn tissue
(Figure S2A) nor in SDH total homogenates (Figure S2B).
To test whether Fyn kinase was required for the BDNF-medi-
ated increase in GluN2B phosphorylation and synaptic localiza-
tion, we treated SDH tissue with BDNF and TAT-Fyn39-57. We
found that co-administration of TAT-Fyn39-57 abolished the in-
crease in phosphorylation of GluN2B at Tyr1472 (p = 0.99) andCell Reports 17, 2753–2765, December 6, 2016 2757
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Figure 4. Fyn but Not Src Directly Mediates the Potentiation of GluN2B-Containing NMDAR Responses at Lamina I Synapses
(A) Plot of initial versus final NMDAR charge transfer values (left) and averaged traces (right) for recordings on naive lamina I neurons with control internal solution
(n = 5), EPQ(pY)EEIPIA (n = 6), EPQ(pY)EEIPIA + Src40-58 (n = 5), or EPQ(pY)EEIPIA + Fyn39-57 (n = 6) in the patch pipette.
(B) Subtraction of final mEPSCs from initial mEPSCs in BDNF pre-treated slices yields a BDNF-sensitive mEPSC component (n = 10).
(C) Left: average initial mEPSC traces from slices pre-treated with TCN-201 (n = 12) versus BDNF and TCN-201 (n = 8) (top) or Ro25-6981 (n = 12) versus BDNF
and Ro25-6981 (n = 6) (bottom). Right: plot of normalized charge transfer values during initial and final recording periods for slices pre-treated with BDNF (n = 10),
BDNF and Ro25-6981 (n = 4), or BDNF and TCN-201 (n = 6), with inset average mEPSC traces. *p < 0.05 compared to initial charge transfer value for given
treatment. Scale bars, 100 ms (x axes); 5 pA (y axes).
All current traces and plots are represented as means ± SEM.the increase in total synaptosomal GluN2B (p = 0.93) observed
for BDNF alone (n = 8 slices, Figure 5B, middle). In slices treated
with TAT-Scbld-Fyn and BDNF, we found an increase in phos-
phorylated GluN2B (p = 0.049) and total GluN2B (p = 0.28)
compared to control-treated slices, albeit below the significance
threshold for the latter (n = 8 slices). Importantly, the increase in
phosphorylation of Fyn at Tyr420 was preservedwhen slices were
treated with BDNF and TAT-Fyn39-57 (n = 8 slices, p = 0.025;
Figure 5B, top), showing that TAT-Fyn39-57 blocks Fyn-GluN2B
interactions rather than the regulation of Fyn activity itself. These
findings together suggest that synaptic NMDAR currents in lam-
ina I neurons are potentiated following PNI by BDNF-induced
stimulation of TrkB, activation of Fyn kinase, and subsequent
phosphorylation of GluN2B-containing NMDARs.
BDNF-Mediated Disinhibition Is Required for the
Potentiation of GluN2B NMDARs by Fyn after PNI
BDNF is a well-knownmediator of PNI-induced pain hypersensi-
tivity via TrkB-mediated blockade of KCC2 and subsequent sup-2758 Cell Reports 17, 2753–2765, December 6, 2016pression of GABAA- and glycine-mediated inhibition of neurons
in spinal lamina I (Beggs and Salter, 2013; Ferrini and De
Koninck, 2013). Hence, we wondered whether this type of
disinhibition may be required for the potentiation of NMDAR
mEPSCs in lamina I neurons. As GABAA and glycine receptors
are permeable to HCO3
, in addition to Cl, disinhibition driven
by blockade of KCC2 is dependent upon HCO3
 efflux (Price
et al., 2009; Staley et al., 1995) and can be reversed by lowering
intracellular HCO3
 via inhibiting carbonic anhydrase (Kaila et al.,
2014). Therefore, we examined the potential involvement of
disinhibition in the BDNF-mediated potentiation of NMDAR
currents by using the membrane-permeant inhibitor of carbonic
anhydrase, acetazolamide. Acetazolamide has been found to
reverse depolarizing shifts in GABAA-receptor currents in lamina
I neurons (Ferrini et al., 2013).
Pre-treating slices from naive rats with acetazolamide (10 mM)
together with BDNF prevented the potentiation of NMDAR
mEPSCs induced by BDNF pre-treatment alone (Figure 6A, left).
Specifically, the NMDAR charge transfer in neurons pre-treated
BA
Figure 5. BDNF Activates Fyn but Not Src to Drive Trafficking and
Phosphorylation of GluN2B NMDARs Selectively at Superficial Dor-
sal Horn Synapses
(A) Fyn or Src were immunoprecipitated from synaptic fractions of SDH.
Western blots using phospho-specific antibodies (right), with phosphorylation
levels normalized to total protein levels (left). *p < 0.05, n = 6.
(B) Western blots from synaptic fractions of SDH treated with either saline,
BDNF, BDNF and TAT-Fyn39-57, or BDNF and TAT-Scbld-Fyn for 70 min.
Blots (n = 8, right) were probed with the antibodies indicated. Phospho-Fyn
was normalized to Fyn and then to beta-actin as a loading control while all
other targets were normalized to beta-actin directly (left). *p < 0.05 using one-
way ANOVA with Tukey’s post hoc test.
All plots are represented as means ± SEM.with BDNF and acetazolamide (3.24 ± 0.34 pC, n = 8 neurons)
wassignificantly less than that inneurons treatedwithBDNFalone
(p = 0.0045) and was not significantly different from that in un-
treated neurons from naive rats (3.20 ± 0.22 pC, n = 20 neurons,
p = 0.92). Also, the in-recording decline of NMDAR mEPSCs,
characteristic of neurons pre-treated with BDNF alone was not
seen in neurons pre-treated with BDNF together with acetazol-
amide (Figure 6A, right). We found that pre-treating slices from
naive rats with acetazolamide alone had no significant effect
on NMDAR mEPSCs, suggesting that disinhibition does not
regulate NMDAR currents under basal conditions (Figure 6B).
However, in recordings from rats with PNI, treating slices withacetazolamide prior to recording significantly reduced the
amplitude of the initial NMDAR mEPSCs to 3.94 ± 0.46 pC (n = 7
neurons; p = 0.035 compared to PNI alone)—a level not different
from that of the charge transfer in neurons from rats without PNI
(Figure 6C, left, p = 0.88). Acetazolamide pre-treatment also
prevented the in-recording decline of NMDAR mEPSCs in rats
with PNI (Figure 6C, right). It is conceivable that the effects of
acetazolamidemight have been due to blockade of BDNF activa-
tion of TrkB receptors. However, we found that acetazolamide
(10 mM) did not affect activation of TrkB by BDNF (Figure S3)
and thus acetazolamide was not acting to prevent BDNF from
activating TrkB.
In contrast to SDH tissue treated with BDNF alone, treat-
ment of slices with BDNF and acetazolamide prevented the
BDNF-dependent increase in phosphorylation of Fyn at Tyr420
(p = 0.97) as well as the increase in phosphorylated GluN2B
(pY1472, p = 0.99) and total GluN2B (p = 0.99) in SDH synapto-
somes (n = 8 slices, Figure 6D; Data S1). Moreover, treatment
of slices with acetazolamide alone had no effect on Fyn phos-
phorylation at Tyr420 (p = 0.94), GluN2B phosphorylation at
Tyr1472 (p = 0.99), or total synaptic GluN2B levels (p = 0.99,
n = 8 slices, Figure 6D), suggesting there is no basal level of disin-
hibition within the naive SDH. Similarly, treatment with either
acetazolamide or acetazolamide and BDNF had no effect on
levels of pY420 Fyn, pY1472 GluN2B, or GluN2B at deep dorsal
horn and ventral horn synapses (Figure S4). Thus, we conclude
that BDNF-induced disinhibition is necessary for the Fyn-medi-
ated potentiation of GluN2B-containing NMDARs produced by
exogenous BDNF or by PNI.
KCC2 Downregulation Primes Lamina I Neurons for
NMDAR Potentiation by BDNF
To test whether the disinhibition mediated by suppressing KCC2
is sufficient to potentiate synaptic NMDAR responses, we used
the pharmacological inhibitor of KCC2, VU0240551 (Delpire
et al., 2009). We applied VU0240551 to spinal slices from naive
rats at a concentration (50 mM) known to increase intracellular
[Cl] and decrease GABA-mediated inhibition (Doyon et al.,
2011). Pre-treating slices with VU0240551 (n = 12 neurons) did
not significantly alter the initial NMDARmEPSCs: charge transfer
(3.63 ± 0.31 pC, p = 0.25) was not different from slices with no
VU0240551 pre-treatment (Figure 7A, left). Also, VU0240551-
treated neurons did not display any time-dependent change in
NMDAR charge transfer during recordings (Figure 7A, right).
As suppressing KCC2 function did not cause a potentiation of
synaptic NMDAR responses per se, we asked whether this form
of disinhibition may gate the potentiation of NMDAR mEPSCs
by BDNF. In lamina I neurons from vehicle-treated slices of naive
rats, bath-applying exogenous BDNF (100 ng/mL) after the
start of whole-cell recording failed to produce potentiation of
NMDAR mEPSCs and instead caused a small inhibition of syn-
aptic NMDAR responses (n = 11 neurons, Figure 7B). However,
in recordings from neurons in spinal slices that had been pre-
treated with VU0240551, bath-applying BDNF (100 ng/mL) dur-
ing the recording significantly increased NMDAR charge transfer
(n = 5 neurons, p = 0.0072, Figure 7B).
In biochemical experiments, we found that BDNF pre-treat-
ment reduced the level of KCC2 in the SDH (n = 8 slices,Cell Reports 17, 2753–2765, December 6, 2016 2759
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Figure 6. The Potentiation of NMDAR mEPSCs by BDNF/PNI Requires Disinhibition
(A) Left: plot of initial NMDAR charge transfer for slices pre-treated with saline (white), BDNF (black), BDNF and 10 mM acetazolamide (gray), or acetazolamide
alone (light gray). Right top: average initial mEPSCs from naive slices pre-treated with BDNF (black) or with BDNF and 10 mM acetazolamide (gray). Right bottom:
average mEPSCs for slices pre-treated with BDNF and 10 mM acetazolamide, during initial (gray) and final (black) recording periods.
(B) Initial average mEPSCs for slices pre-treated with 10 mM acetazolamide (n = 7) compared to saline pre-treated slices (n = 20).
(C) Left: representative mEPSC traces during initial (gray) and final (black) recording periods from lamina I neurons of the same PNI rat whereby one slice was pre-
treated with control solution (top) and a separate slice was pre-treated with 10 mM acetazolamide for 72 min (bottom). Right: plot of normalized charge transfer
values during initial and final recording periods. *p < 0.05 compared to initial charge transfer value for a given treatment. Scale bars, 100ms (x axes); 5 pA (y axes).
(D) Western blots from synaptic fraction of SDH treated with either saline, BDNF, BDNF and acetazolamide, or acetazolamide alone. Statistical significance
(*p < 0.05, n = 8 for all treatments) was determined using one-way ANOVA with Tukey’s post hoc test.
All current traces and plots are represented as means ± SEM.p = 0.042/0.0034, Figure 7C, top/bottom; Data S1) but not in
the deep dorsal horn and ventral horn (Figure S4). Moreover,
this reduction was not abolished by pre-treatment of BDNF
with acetazolamide (n = 8 slice, p = 0.047, Figure 7C, top) nor
TAT-Fyn39-57 (n = 8 slices, p = 0.00020, Figure 7C, bottom).
As acetazolamide and TAT-Fyn39-57 did block the phosphoryla-
tion and potentiation of GluN2B NMDARs by BDNF, this finding
further supports that KCC2 downregulation alone is not sufficient
to induce potentiation of NMDARs. Thus, we conclude that not
only does BDNF suppress KCC2-dependent inhibition but that
the resultant disinhibition permits the action of this neurotrophin
to potentiate synaptic GluN2B NMDARs via Fyn activation in
lamina I neurons.
KCC2 level is regulated by several mechanisms following
induction of neuronal activity (Chamma et al., 2013; Lee et al.,
2011). To investigate whether calpain-mediated cleavage may
be responsible for the loss of KCC2 upon BDNF treatment, we2760 Cell Reports 17, 2753–2765, December 6, 2016measured levels of fodrin—a well-characterized calpain sub-
strate (Siman et al., 1984)—as a readout for calpain activity.
We found no changes in full-length (250 kDa) or calpain-cleaved
(150/145 kDa) fragments of fodrin after BDNF treatment in SDH
synaptosomes (Figure S5A) or SDH homogenates (Figure S5B),
suggesting calpain was not activated by BDNF under these
conditions.
Raising Intracellular Ca2+ Permits BDNF-Induced
Potentiation of NMDAR mEPSCs
We next investigated how disinhibition may gate subsequent
potentiation of synaptic NMDARs by BDNF. The acetazolamide
experiments suggest that a rise in intracellular Cl does not
permit the potentiation of synaptic NMDARs by the TrkB/Fyn
pathway. As disinhibition also induces an increase in intracel-
lular [Ca2+] ([Ca2+]i) in spinal neurons (Darbon et al., 2002),
it is possible that a rise in [Ca2+]i gates the effect of BDNF on
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Figure 7. Downregulation of KCC2 Activity Gates Potentiation of NMDAR mEPSCs by Exogenous BDNF
(A) Average initial mEPSC traces (middle) and associated NMDAR charge transfer values (left) in control-treated slices (white) or slices pre-treated with 50 mM
VU0240551 for 80 ± 3min (gray, n = 12). Right: averagemEPSC traces (inset) and normalized charge transfer values for slices pre-treated with VU0240551 during
initial and final recording periods.
(B) Left: averagemEPSC traces from slices pre-treated VU0240551 for 60+min (n = 5). Following a control period of recording (black trace), 100 ng/mL BDNFwas
acutely perfused during recording for 10+ min (gray trace). Right: NMDAR charge transfer during acute administration of BDNF normalized to a control recording
period for untreated (left bar) and VU0240551 pre-treated (right bar) slices. *p < 0.05. Scale bars, 100 ms (x axes); 5 pA (y axes).
(C) Synaptic fraction from SDH treated with the indicated agents for 70 min. KCC2 protein levels were normalized to beta-actin as a loading control (left).
Statistical significance (*p < 0.05, n = 8) was determined one-way ANOVA with Tukey’s post hoc test.
All current traces and plots are represented as means ± SEM.NMDARs at lamina I synapses. Hence, we studied NMDAR
mEPSCs in lamina I neurons of naive rats under conditions that
permit, or prevent, an increase in [Ca2+]i. To facilitate increasing
[Ca2+]i we used an extracellular recording solution lacking Cd
2+
and Mg2+ to permit and enhance calcium influx through
voltage-gated calcium channels and NMDARs, respectively.
Moreover, we reduced intracellular Ca2+ buffering by using
100 mM EGTA in the intracellular pipette solution. Under these
recording conditions, NMDAR mEPSCs at 40 mV remained
constant during 20min of whole-cell recording: the charge trans-
fer of inward NMDARmEPSCs was not significantly different be-
tween the 10–15 min recording period (Q = 0.45 ± 0.11, n = 6)
and the 15–20 min recording period (Q = 0.44 ± 0.11 pC, n = 6,
p = 0.75; Figure S6). However, we found under these recording
conditions that administrating exogenous BDNF induced an
increase in NMDAR mEPSCs (Figure S7): average NMDAR
charge transfer significantly increased from0.45 ± 0.11 pC dur-
ing baseline recording to 0.83 ± 0.16 pC during administrationof BDNF (n = 6 neurons, p = 0.0021, Figure S7B, left). This BDNF-
induced increase in NMDAR charge transfer was not observed in
neurons where we greatly increased intracellular Ca2+ buffering
by replacing EGTA (100 mM) with the more rapid buffer BAPTA
at the higher concentration of 10 mM (Figure S7B, right; baseline
Q = 0.45 ± 0.10 pC, BDNF Q = 0.51 ± 0.10 pC, n = 5). Thus,
an increase in [Ca2+]i within the lamina I neuron recorded is
permissive for the subsequent potentiation of synaptic NMDARs
by BDNF.
DISCUSSION
Given the importance of lamina I neurons to the integration and
output of spinal nociceptive signals (Braz et al., 2014; Prescott
et al., 2014), we investigated whether glutamatergic responses
at lamina I synapses are altered in a model of neuropathic
pain. We found that unitary synaptic NMDAR currents in lamina
I spinal neurons are potentiated following traumatic peripheralCell Reports 17, 2753–2765, December 6, 2016 2761
nerve injury. The AMPAR component of the mEPSCs, by
contrast, was unchanged by nerve injury indicating that the
quantal release of glutamate onto lamina I neurons is not altered
by PNI, consistent with previous reports (Chen et al., 2014a; Li
et al., 2016). Rather, our findings indicate that the increase in
the NMDAR component of the mEPSCs in the nerve-injured
state ismediated post-synaptically by enhancement of NMDARs
in the lamina I neurons themselves. The most parsimonious
signaling cascade suggested by our results is that activation of
TrkB by its cognate ligand BDNF leads to activation of Fyn kinase
and potentiation of GluN2B-containing synaptic NMDARs. Un-
expectedly, the potentiation of NMDARs by the BDNF-TrkB-
Fyn signaling pathway requires prior and sustained KCC2-
dependent disinhibition, as we found that blocking disinhibition
with acetazolamide abolished the enhancement of lamina I
NMDARs by exogenously administered BDNF or nerve injury.
Thus, taking our evidence together suggests that within individ-
ual lamina I neurons, BDNF-mediated disinhibition leads to a
post-synaptic rise in [Ca2+]i that gates potentiation of synaptic
GluN2B NMDARs, by the TrkB-Fyn signaling pathway, in a
feed-forward cycle that is activated by nerve injury.
Our findings indicate that ongoing release of BDNF and contin-
uous activation of TrkB-Fyn signaling is required to maintain the
basal potentiation of NMDAR responses at lamina I synapses.
Specifically, we found that NMDAR mEPSCs in lamina I neurons
from animals with PNI were robustly potentiated even several
hours after sectioning—potentiation that was reversed by acute
blockade of TrkB, Fyn, or disinhibition. From these findings, we
conclude that following nerve injury, a BDNF-mediated signaling
cascade that includes spinal disinhibition and activation of TrkB
and Fyn within individual lamina I neurons is being continuously
activated and is required for basal NMDAR potentiation. Thus,
the potentiation of NMDARs at lamina I synapses is not an event
induced by PNI and maintained independently, like activity-
induced long-term potentiation. A form of long-term potentiation
has been shown at lamina I synapses following peripheral inflam-
mation (Ikeda et al., 2006), and it is possible that the basal poten-
tiation of synaptic NMDARs observed here can lead to a facilita-
tion of synaptic AMPAR responses following a train of afferent
firing. However, unlike canonical long term potentiation, the
basal potentiation of synaptic NMDARs in lamina I neurons is
maintained by ongoing signaling. This conclusion is consistent
with the behavioral sensitization in PNI models that is reversed
by interfering with specific elements of the signaling cascade.
For example, PNI-induced behavioral sensitization is reversed
by BDNF-TrkB blockers (Coull et al., 2005; Wang et al., 2009),
NMDAR antagonists (Bourinet et al., 2014), SFK inhibitors
(Peng et al., 2010), and blockers of KCC2-dependent spinal
disinhibition (Asiedu et al., 2010; Gagnon et al., 2013; Li et al.,
2016).
Potentiation of NMDAR by SFKs is known to depend upon
tyrosine residues on the GluN2 subunits (Salter and Kalia,
2004) with different SFKs preferentially potentiating NMDARs
comprised of different GluN2 subunits (Salter et al., 2009). The
GluN2 subunit dependency has been worked out most exten-
sively with NMDAR responses in hippocampal CA1 neurons. In
CA1 neurons, Fyn selectively phosphorylates and enhances
the activity of GluN2B-containing NMDARs, while Src phos-2762 Cell Reports 17, 2753–2765, December 6, 2016phorylates and enhances GluN2A-containing receptors (Yang
et al., 2012). In spinal lamina I neurons, NMDAR mEPSCs are
dominated by GluN2B subunits with little contribution from
GluN2A-containing receptors (Hildebrand et al., 2014). This
GluN2B dominance is consistent with our findings showing
that the potentiation of NMDAR mEPSCs after PNI is dependent
on Fyn, but not Src activity. Indeed, we show that Fyn directly
potentiates GluN2B NMDAR responses at lamina I synapses
and that BDNF mediates an increase in the activated/phosphor-
ylated forms of Fyn and GluN2B proteins selectively at SDH syn-
apses. Thus, we conclude that GluN2B-containing NMDARs in
lamina I neurons are selectively enhanced by Fyn kinase, acti-
vated downstream of TrkB. Conversely, although phosphoryla-
tion of NMDARs by Src has been implicated in pain hypersensi-
tivity (Liu et al., 2008), GluN2A-containing NMDARs contribute
little to NMDAR mEPSCs in lamina I neurons (Hildebrand et al.,
2014). We observe here that the Src inhibitor peptide had no
effect on the potentiation of NMDAR mEPSCs after PNI and
that BDNF did not alter GluN2A expression or phosphorylation
at SDH synapses. We therefore conclude that the regulation of
NMDARs by Src that is linked to pathological pain occurs at a
locus in the pain transmission pathway other than in lamina I
spinal neurons. Potential sites where Src-dependent potentia-
tion of NMDARs may mediate pain hypersensitivity include
presynaptic afferents (Chen et al., 2014b) and lamina II neurons
(Wang et al., 2016).
The reversal of PNI-induced potentiation of NMDAR mEPSCs
by acetazolamide implies that spinal disinhibition is required for
the potentiation of NMDAR responses at lamina I synapses. One
possible mechanism is that the increase in Cl- that is produced
by decreased KCC2 activity in individual lamina I neurons (Coull
et al., 2003) gates the potentiation of NMDARs by Fyn. However,
acetazolamide should not alter intracellular Cl concentration,
as it blocks intracellular HCO3
 production to reverse disinhibi-
tion (Staley et al., 1995). We also found that treating naive slices
with the KCC2 antagonist, VU0240551, had no effect on NMDAR
mEPSCs in lamina I neurons. Thus, an increase in intracellular
Cl is not sufficient for the potentiation of NMDARs at lamina I
synapses. One potential player in this process is the protein
tyrosine phosphatase STEP61. STEP61 dephosphorylates and
inactivates Fyn, and not Src, and dephosphorylates GluN2B,
leading to internalization of GluN1/GluN2B receptor complexes
(Azkona et al., 2016; Xu et al., 2015). Disinhibition may thereby
drive a downregulation of STEP61 to gate NMDAR potentiation
by BDNF. As neither the disinhibition pathway alone nor the
BDNF-TrkB signaling pathway alone is sufficient to cause poten-
tiation of synaptic NMDAR currents, these processes appear to
require coincident activation to cause potentiation of NMDARs.
Together, the data indicate that we have discovered a form of
molecular coincidence detection in lamina I neurons that re-
quires ongoing inputs—BDNF-TrkB signaling and spinal disinhi-
bition—to mediate the potentiation of synaptic excitation.
The relationship between disinhibition and NMDAR potentia-
tion is a feed-forward mechanism for accelerating enhancement
of overall excitability of lamina I neurons. The relationship may
also be reciprocal. It has recently been shown that NMDAR ac-
tivity and an increase in [Ca2+]i are required for the downregula-
tion of KCC2 in the brain and spinal cord (Chamma et al., 2013;
Lee et al., 2011; Zhou et al., 2012), implying a vicious cycle within
lamina I neurons whereby loss of inhibition gates an increase in
excitation and vice versa. The potential therapeutic implications
of such a cycle might be that blocking disinhibition may second-
arily relieve the permissive effect that is needed for NMDAR
potentiation, while blocking NMDAR activity may relieve the
drive to downregulate KCC2. In support, blockade of the individ-
ual molecular players in this pathway has been shown to reverse
nerve-injury induced hypersensitivity in vivo, including BDNF
(Coull et al., 2005), KCC2 downregulation (Li et al., 2016), disin-
hibition (Coull et al., 2003; Lee and Prescott, 2015), Fyn activa-
tion (Abe et al., 2005; Katsura et al., 2006; Liu et al., 2014), inter-
actions between Fyn and pY1472-GluN2B (Matsumura et al.,
2010), and GluN2B function (Kim et al., 2012). Thus, our results
provide a biologically plausible model of molecular coupling
within lamina I neurons that may explain how multiple signaling
pathways might each be necessary to sustain nerve-injury
induced hypersensitivity.
We speculate that our findings have implications beyond
understanding nerve-injury induced hypersensitivity, as BDNF
has been implicated in other types of pain hypersensitivity. In in-
flammatory hypersensitivity, BDNF appears to be released from
nociceptive primary afferents, and knocking down nociceptor
BDNF selectively attenuates behavioral hypersensitivity induced
by peripheral inflammation (Mannion et al., 1999; Zhao et al.,
2006) and burst stimulation of afferents drives BDNF release
(Lever et al., 2001). In morphine-induced hyperalgesia, BDNF
released from activated spinal microglia mediates a disinhibition
in lamina I neurons that drives sensitization (Ferrini et al., 2013).
Thus, our present findings raise the possibility that BDNF-medi-
ated disinhibition may drive NMDAR potentiation in a number of
hypersensitivity states in the spinal cord. Finally, both BDNF-
evoked disinhibition and potentiation of synaptic NMDARs can
occur at synapses throughout the brain, and coupling between
these pathways could underlie neuronal hyperexcitability in dis-
orders ranging from addiction to traumatic brain injury to epi-
lepsy (Ferrini and De Koninck, 2013; Kalia et al., 2008; Semaan
et al., 2015; Shulga et al., 2008; Vargas-Perez et al., 2014). We
therefore propose that our model of coincident detection be-
tween facilitation of NMDAR-mediated excitation and loss of
KCC2-dependent inhibition may be broadly relevant to synaptic
signaling throughout the CNS.
EXPERIMENTAL PROCEDURES
Animals
All experiments involving rats and their care were performed in accordance
with the recommendations of the Canadian Council on Animal Care and
were according to the animal care regulations and policies of the Hospital
for Sick Children, Toronto. We performed all experiments on male adult
(350–450 g) Sprague Dawley (SD) rats, except for the experiments in Figure 3A,
which utilized juvenile (P20–P22) SD rats.
Peripheral Nerve Injury and Behavioral Testing
As previously described (Mosconi and Kruger, 1996; Pitcher et al., 1999), we
used a PNI model of neuropathic pain to study pathological pain signaling. Un-
der isoflurane anesthesia, we implanted a 2-mm long polyethylene cuff around
the sciatic nerve of adult SD rats. Ten to 17 days after surgery, animals were
tested for behavioral hypersensitivity compared to baseline by measuring me-
chanical paw withdrawal threshold with von Frey filaments. Animals used forspinal slice electrophysiology typically had a reduction in paw withdrawal
threshold from 15 g to 4 g, which was restricted to the ipsilateral paw.
Spinal Cord Isolation
We anaesthetized male SD rats through intraperitoneal (i.p.) injection of 3 g/kg
urethane (Sigma). As previously described (Hildebrand et al., 2014), we rapidly
dissected out the lumbar spinal cord and immediately placed the cord in an
ice-cold, oxygenated protective modified artificial cerebrospinal fluid (pACSF)
solution. Parasagittal spinal slices (300 mm) were cut from an L3–L6 section of
lumbar spinal cord.
Electrophysiological Recordings on Lamina I Spinal Cord Neurons
We visualized cells using infrared differential interference contrast (IR-DIC) op-
tics and neurons from lamina I were selected based upon their location dorsal
to the substantia gelatinosa layer, within 50 mmof the white matter (Hildebrand
et al., 2014). Although this selection criteria enriches for a population of mainly
lamina I neurons, we cannot formally exclude the possibility that a smaller frac-
tion of recorded neurons were in lamina II.
The extracellular recording solution consisted of an artificial cerebrospinal
fluid (ACSF) solution containing (in mM): 125 NaCl, 20 D-glucose, 26 NaHCO3,
3 KCl, 1.25 NaH2PO4, 2 CaCl2, and 1 MgCl2 as well as 500 nM TTX, 10 mM
Cd2+, 10 mM strychnine and 10 mM bicuculline to block voltage-gated Na+
channel, voltage-gated Ca2+ channel, glycinergic and GABAergic currents,
respectively. We pulled patch-clamp pipettes with resistances of 4–8 MU.
The internal patch pipette solution contained (in mM): 105 Cs-gluconate,
17.5 CsCl, 10 BAPTA, 10 HEPES, 5 QX-314, 2 MgATP, 0.5 Na2GTP (pH =
7.25, 295 mOsm), except in a subset of experiments where 10 BAPTA was
replaced with 0.1 EGTA (Figure S7).
Neurons typically had access resistances below 20 MU and leakage cur-
rents >100 pA at a holding potential (Vh) of 70 mV. As previously described
(Hildebrand et al., 2014), we generated averaged mEPSCs for time intervals
ranging between 5 and 10 min, typically with 30 to 50 events per averaged
trace. For recordings of NMDAR-mEPSCs at +60 mV, we broke through to
the whole-cell configuration at 60 mV and gradually adjusted the holding
potential to +60 mV. Thus, analysis of ‘‘initial’’ NMDAR-mEPSC currents
was based on averages from 5–15 min after whole-cell configuration. We
selected for mEPSCs containing a NMDAR component at +60 mV by
excluding mEPSCs that exhibited complete decay within 100 ms. For experi-
ments with conditions that promoted a rise in intracellular Ca2+ (Figures S6 and
S7), recordings were done at a holding potential of40 mV, on neurons with a
mEPSC frequency >1 Hz.
Compounds and Perfusion
For electrophysiology experiments, D-AP5, bicuculline methochloride, K252a,
Ro25-6981, TCN-201. and VU 0240551 were from Tocris Bioscience. TTX was
from Alomone labs. Recombinant BDNF protein was from Abcam, while TrkB-
Fc and TrkB-IgG were from R&D Systems. Ionomycin, PP2 and SU6656 were
from Calbiochem. The Src40-58 and Fyn39-57 inhibitor peptides as well as
their TAT-linked versions (Liu et al., 2008; Yang et al., 2012) were synthesized
by GenScript. Unless otherwise indicated, all other compounds were ordered
from Sigma-Aldrich. We applied 50 ng/mL BDNF in slice pre-treatment exper-
iments, where prolonged treatment would allow for permeation of BDNF
throughout the slice. A higher concentration of BDNF (100 ng/mL) was used
for acute perfusion to ensure that sufficient levels of BDNF reached the neuron
under study during the shorter time course of the recordings.
Isolation of Synaptic Fractions and Biochemical Analyses
For biochemical studies, the lumbar spinal cord was sectioned horizontally
with a vibratome into an approximately 300 mm thick horizontal SDH section
and a second section containing the remainder of the spinal cord. Isolation
of synaptic fractions was performed as previously described (Xu et al.,
2009). Briefly, tissues were lysed in Dounce tissue grinders (Wheaton)
in 1 mL ice-cold TEVP buffer supplemented with complete protease inhib-
itor cocktail (Roche). Aliquots of lysates were saved for further analyses as
total homogenates. The rest of lysates went through two spins (10 min at
1,000 3 g and 15 min at 12,000 3 g) to obtain synaptic fractions. Samples
(30 mg) were loaded on 8% SDS-PAGE and transferred to nitrocelluloseCell Reports 17, 2753–2765, December 6, 2016 2763
membrane (Bio-Rad). Membranes were blocked in 5% BSA in TBS + 1%
Tween-20 (TBS-T) and incubated with primary antibodies overnight (anti-
pY416 Src family [1:1,000] and anti-pY527 Src family [1:1,000] from Upstate;
anti-Fyn [1:2,000], anti-Src [1:2,000], anti-KCC2 [1:2,000] and anti-actin
[1:5,000] from Santa Cruz; anti-pY1472 GluN2B [1:1,000] and anti-pY1325
GluN2A [1:1,000] from PhosphoSolutions; anti-GluN2B [1:2,000] and anti-
GluN2A [1:2,000] from Millipore; anti-fodrin [1:5,000] from Enzo Life Sciences)
in 5%BSA+TBS-T. Membranes were washed three times with TBS-T and then
incubated with horseradish peroxidase (HRP)-coupled secondary antibodies
(anti-mouse or anti-rabbit, Pierce, 1:5,000) for 2 hr at room temperature.
Membranes were developed using Chemiluminescent Substrate kit (Pierce)
and visualized by a G:BOX with the GeneSnap software (Syngene). All densi-
tometric bands were quantified using ImageJ (NIH).
Data Analysis
We used Microcal Origin 8.5 (Northampton) and Clampfit10 (Molecular
Devices) for data analysis. All data are given as means ± SEM. We performed
statistical comparisons of data using both Student’s paired and unpaired
t tests as well as one-way ANOVAs followed by a Tukey’s test for means com-
parisons. We considered p < 0.05 to be statistically significant.
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